Former Names FVB/N-Tg(Slc6a3-PARK2*Q311X)AXwy/J (Changed: 08-JUL-09 ) Type Coisogenic; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System Hemizygote x Noncarrier (Female x Male) 09-FEB-10 Species laboratory mouse Generation F?+F3 (14-MAR-11)
Generation DefinitionsDonating Investigator X. William Yang, University of California Los Angeles Description
Hemizygous Parkin-Q311X(A) mice are viable and fertile, with expression of a FLAG-tagged, C-terminal truncated human parkin-Q311X mutation associated with Turkish early-onset Parkinson's disease directed to dopaminergic neurons of the substantia nigra pars compacta (SNc) and ventral tegmentum area (VTA) by the mouse Slc6a3 promoter/enhancer sequences. Parkin-Q311X(A) mice (derived from founder line A) have expression of the FLAG-tagged parkin-Q311X protein in dopaminergic neurons at a level that is approximately equivalent to or just below that expected from a heterozygous endogenous parkin allele. Parkin-Q311X(A) mice exhibit multiple late-onset and progressive hypokinetic motor deficits, progressive dopaminergic neuron dysfunction and degeneration, and age-dependent accumulation of proteinase K-resistant endogenous alpha-synuclein. Compared to founder line D, Parkin-Q311X(A) mice have a higher transgene copy number that results in more robust and earlier onset of hypokinetic motor deficits and more significant dopaminergic (DA) neuron degeneration. These Parkin-Q311X(A) mice represent a robust in vivo model for studying the Parkinson's disease pathogenesis and neurodegeneration elicited by the dominant toxic effects of mutant parkin-Q311X expression.View PD Online Research Q&A with Dr. X. William Yang: The Parkin-Q311X model.
Development
The 200 kb mouse bacterial artificial chromosome (BAC) RP23-408F13 contains the entire 50 kb Slc6a3 gene (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; also called dopamine transporter (DAT)) and other genes in the approximately 100 kb of 5' and 40 kbp of 3' flanking sequences. This BAC was modified by inserting a parkin-Q311X cDNA sequence (FLAG-tagged mutant human parkin gene (PARK2; Parkinson disease (autosomal recessive, juvenile) 2, parkin) carrying the Q311X truncation associated with Turkish early-onset Parkinson's disease and followed by a polyA signal) into Slc6a3 exon 2 upstream of the translation initiation codon. This modified Slc6a3-parkin(Q311X) BAC was microinjected into fertilized FVB/NJ zygotes. Parkin-Q311X mice from founder line A (found to harbor two tandem integrates of the transgene) were subsequently maintained by breeding transgenic mice with wildtype (noncarrier) siblings or FVB/NJ inbred mice for many generations prior to arrival at The Jackson Laboratory. Upon arrival, mice were bred to FVB/NJ inbred mice (Stock No. 001800) for at least one generation to establish the colony.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 017001 129S.B6N-Plk2tm1Elan/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 008084 B6.129P2-Drd4tm1Dkg/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 008843 B6.129P2-Sncgtm1Vlb/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 017946 B6.129S4-Pink1tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 012265 B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 003692 B6;129X1-Sncatm1Rosl/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 013725 B6;SJL-Tg(LRRK2)66Mjff/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 018768 B6N.Cg-Tg(SNCA*E46K)3Elan/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 016120 C57BL/6-Lrrk1tm1.1Mjff/J 012444 C57BL/6-Lrrk2tm1Mjfa/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 016122 C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J 016121 C57BL/6N-Lrrk2tm1.1Mjff/J 016123 C57BL/6N-Sncatm1Mjff/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010788 FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 017000 STOCK Tg(SNCA*E46K)3Elan/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012441 STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (109 strains)
Strains carrying other alleles of Slc6a3
006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 016583 C57BL/6N-Tg(Slc6a3-icre/ERT2)2Gloss/J View Strains carrying other alleles of Slc6a3 (2 strains)
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Parkinson Disease 2, Autosomal Recessive Juvenile; PARK2
- Potential model based on transgenic expression of an ortholog of a human gene that is associated with this disease. Phenotypic similarity to the human disease has not been tested. Leprosy, Susceptibility to, 2; LPRS2 (PARK2)
Lung Cancer (PARK2)
Ovarian Cancer (PARK2)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Tg(Slc6a3-PARK2*Q311X)AXwy/0
FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy
- behavior/neurological phenotype
- abnormal locomotor activation
- at 16-19 months, mice make significantly fewer hindlimb steps compared to controls (MGI Ref ID J:146833)
- abnormal touch/ nociception
- in adhesive removal tests, at 16-19 months, mutants show significant deficits at 16-19 months (MGI Ref ID J:146833)
- impaired balance
- in beam tests, mice show more errors per step while traversing the beam compared with age; significant age effect is observed with performance in 3-6 month-old animals being comparable to controls but markedly impaired at 16-19 months (MGI Ref ID J:146833)
- nervous system phenotype
- abnormal substantia nigra morphology
- in the middle and caudal regions of the substantia nigra, significant numbers of alpha synuclein positive neurons are detected at 16 months, but not at 3 months; a chronic accumulation of proteinase K-resistant alpha-synuclein in midbrain neurons is observed in mutants (MGI Ref ID J:146833)
- dopaminergic neurons in the substantia nigra display oxidative protein damage at 16 months which is not as prevalent in wild-type mice (MGI Ref ID J:146833)
- decreased dopamine level
- in 19-21 month-old animals, dopamine (DA) levels are significantly reduced compared to controls which correlates with multiple hypokinetic motor deficits like open-field motor activity and vertical plane entries (MGI Ref ID J:146833)
- loss of dopaminergic neurons
- at 16 months, mice have a 40% reduction in tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta (SNc) coincident with a 30% reduction in total neuron number indicating a late-onset dopaminergic neuron loss (MGI Ref ID J:146833)
- integument phenotype
- abnormal touch/ nociception
- in adhesive removal tests, at 16-19 months, mutants show significant deficits at 16-19 months (MGI Ref ID J:146833)
- homeostasis/metabolism phenotype
- decreased dopamine level
- in 19-21 month-old animals, dopamine (DA) levels are significantly reduced compared to controls which correlates with multiple hypokinetic motor deficits like open-field motor activity and vertical plane entries (MGI Ref ID J:146833)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Developmental Biology Research
Neurodevelopmental Defects
Neurobiology Research
Ataxia (Movement) Defects
Cortical Defects
Neurodegeneration
Neurodevelopmental Defects
Parkinson's Disease
Park2 (parkin) mutants
Tremor Defects
Research Tools
Neurobiology Research
| Allele Symbol | Tg(Slc6a3-PARK2*Q311X)AXwy | ||
|---|---|---|---|
| Allele Name | transgene insertion A, X William Yang | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | Parkin-Q311X line A; Parkin-Q311X(A); TgA; | ||
| Mutation Made By | X. William Yang, University of California Los Angeles | ||
| Strain of Origin | FVB/NJ | ||
| Expressed Gene | PARK2, parkinson protein 2, E3 ubiquitin protein ligase (parkin), human | ||
| Promoter | Slc6a3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, mouse, laboratory | ||
| Molecular Note | A 200 kb mouse bacterial artificial chromosome (BAC) RP23-408F13 contains the entire 50 kb Slc6a3 gene (solute carrier family 6 (neurotransmitter transporter, dopamine), member 3; also called dopamine transporter (DAT)) and other genes in the approximately 100 kb of 5' and 40 kbp of 3' flanking sequences. This BAC was modified by inserting a parkin-Q311X cDNA sequence (FLAG-tagged mutant human parkin gene (PARK2; Parkinson disease (autosomal recessive, juvenile) 2, parkin) carrying the Q311X truncation associated with Turkish early-onset Parkinson's disease and followed by a polyA signal) into Slc6a3 exon 2 upstream of the translation initiation codon. This modified Slc6a3-parkin(Q311X) BAC was microinjected into fertilized FVB/NJ zygotes. Line A (found to harbor two tandem integrates of the transgene) was subsequently established. [MGI Ref ID J:146833] | ||
Genotyping Protocols
Tg(Slc6a3-PARK2*Q311X), Melt Curve Analysis
Tg(Slc6a3-PARK2*Q311X), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW. 2009. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 29(7):1962-76. [PubMed: 19228951] [MGI Ref ID J:146833]
Animal Health Reports
Room Number AX11
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, hemizygous mice may be bred to wildtype (noncarrier) siblings or to FVB/NJ inbred mice (Stock No. 001800). Mating System Hemizygote x Noncarrier (Female x Male) 09-FEB-10 Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $232.00 Female or Male Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy
Price per Pair (US dollars $) Pair Genotype $296.00 Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy x Noncarrier $296.00 Noncarrier x Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Pricing for International shipping destinations |
|
Price per mouse (US dollars $) Gender Genotypes Provided Individual Mouse $301.60 Female or Male Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy
Price per Pair (US dollars $) Pair Genotype $384.80 Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy x Noncarrier $384.80 Noncarrier x Hemizygous for Tg(Slc6a3-PARK2*Q311X)AXwy Standard Supply
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
|
|
Repository-Live. Repository-Live represents an exclusive set of over 1500 unique mouse models maintained at The Jackson Laboratory to support a vast array of research areas. The breeding colonies for Repository Strains provide mice for both large and small orders and fluctuate in size depending on current demand for each strain. Repository-live orders are treated as custom orders. Within 2 business days, we respond to each availability inquiry or order with various delivery options. Repository Strains typically are delivered at 4 to 8 weeks of age and will not exceed 12 weeks of age on the day of shipping.
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.